Key facts
- ArriVent BioPharma shares fell nearly 47% on Tuesday after its cancer drug firmonertinib failed a Phase 3 trial.
- Firmonertinib was originally developed by Shanghai Allist Pharmaceuticals.
- The drug is approved in China for certain lung cancers, sold by Allist Pharmaceuticals.
ArriVent BioPharma's shares plummeted nearly 47% on Tuesday after the company announced that its cancer drug, firmonertinib, failed to meet its primary goal in a Phase 3 trial. The drug was originally developed by Shanghai Allist Pharmaceuticals and is approved in China for certain lung cancers.
The setback for firmonertinib, an EGFR inhibitor, occurred despite a rising broader market, with the S&P 500 tracker up 0.83%, the Nasdaq 100 tracker up 0.87%, and the Dow tracker up 0.72% at the time of ArriVent's last trade on October 6, 2026. The company's stock fell 53.76% in intraday trading, reaching a low of 11.36 against a previous close of 28.46.
Analysts noted that the failure highlights the challenges facing Chinese biotech companies as they seek to expand into global markets. The outcome of late-stage trials is critical for a company's investment case, as it provides evidence for regulatory progress and commercial prospects. The specific details of the trial's main outcome measure, comparison treatment, effect size, and safety findings are still pending, which will be crucial in determining the future development path for firmonertinib.